Agomab doses first patient in Phase 2b Crohn's disease study
Tweet Send to a Friend
Agomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, a global Phase 2b study evaluating ontunisertib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




